The regulation of skeletal muscle stem cells during homeostasis and regeneration involves the interplay of multiple mechanisms. The mechanisms by which niche molecules and intrinsic factors regulate muscle stem cell quiescence and properties remain largely unknown. In a series of studies, we investigated Notch as a key mediator of muscle satellite cell stability and fate. Specifically, Notch mediates extrinsic (extracellular matrix) and intrinsic (microRNA) mechanisms to stabilise satellite cells within their niche. Interestingly, Notch/RBPJ-bound regulatory elements are located adjacent to specific collagen genes in adult muscle satellite cells. These molecules are linked to the ECM and constitute putative niche components. Notably, satellite cell-produced collagen V (COLV) is a critical component of the quiescent niche, as conditional deletion of Col5a1 leads to anomalous cell cycle entry and differentiation of satellite cells. Strikingly, COLV specifically regulates quiescence through Calcitonin receptor mediated activity. In other studies, we have identified a microRNA pathway that is modulated by Notch, and it is required for stabilising muscle stem cells in their niche by regulating the migration status of the muscle stem cell. These observations lead us to propose a two-step mechanism for niche occupancy.
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Prof. Shahragim Tajbakhsh obtained a Doctor of Philosophy degree in Biology from Carleton University, Canada (1988) working on the molecular biology of viruses. Following postdoctoral research at the Pasteur Institute he established an independent group in 2001 called \"Stem Cells & Development\" where he has been interested in how stem cells establish and regenerate organs and tissues, with a particular focus on skeletal muscle. The aim of the laboratory is to investigate stem cell properties during development and postnatally to understand how skeletal muscle is established, and how it regenerates during disease, and after injury. Areas of focus include quiescence, niche, self-renewal, symmetric and asymmetric cell divisions, ageing.

Prof. Tajbakhsh is an EMBO member, former Head of the Dept. of Developmental & Stem Cell Biology and co-Director of the \"Laboratory of Excellence\" Consortium, REVIVE, regrouping leading labs working on stem cells (2011-2022). He is member of 2 scientific councils for associations, several SABs and presides on editorial boards of 4 scientific journals. He has participated in a number of EU consortia (FP6, EuroStemCell; FP7, EuroSyStem, Optistem, NotchIT) and received several awards including the Chair of Excellence Louis Pasteur (Institut Pasteur, 2017) and the French Academy of Sciences/Fondation Generale de Santé, for achievements in stem cell research.

The circadian clock is responsible for biological timekeeping on a systemic level. The mammalian central pacemaker is localized in the hypothalamus, in a paired neuronal structure called the suprachiasmatic nucleus (SCN). The discovery that all tissues and virtually all cells contain an intrinsic circadian clock revolutionized the field, providing a conceptual framework towards the understanding of organismal homeostasis and physiological tissue-to-tissue communications ([@art001_ref1]). The circadian clock controls a remarkable array of physiological and metabolic functions through governing a significant portion of the genome. Furthermore, the clock drives cyclic chromatin remodeling associated to circadian transcription, including spatial nuclear organization ([@art001_ref2]). The circadian epigenome shares intimate links with cellular metabolic processes and has remarkable plasticity showing reprogramming during aging and in response to nutritional challenges ([@art001_ref3], [@art001_ref4]). We will present findings that reveal specific molecular connections between chromatin remodelers, metabolic pathways and the circadian clock.
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During the past three decades my research has focused on the molecular mechanisms of transcriptional regulation and chromatin remodeling, specifically in response to changes in signaling transduction and cellular metabolism. In the past twenty years we uncovered the specific role of transcriptional and epigenetic regulators in circadian clock function and deciphered how metabolic circuits intimately connect to the circadian system. Our studies have significantly impacted the fields of transcription, epigenetics, metabolism and endocrinology. Our expertise covers molecular, cellular, physiological and behavioral analysis of circadian rhythms in mammals, including genomics, metabolomics high-throughput profiling and Biocomputing. The high impact of our research is witnessed by the numerous high-profile publications, numerous invitations as plenary speaker at high-profile conferences and by an h-index of 123.

Positions: After PhD in Italy and post-doctoral studies in France and USA (1980-1988), PSC established his research group in Strasbourg, France, with the position of Directeur de Recherche (1989-2006). Moved to University of California, Irvine as Distinguished Professor and Chair of the Department of Pharmacology (2006-2011) and then as Director of the Center for Epigenetics and Metabolism (2011-present) and Donald Bren Professor (2011-present). PSC is also External Professor of the Max-Planck Institute (Germany).

Honors (partial list): EMBO Gold Medal (1994); Grand Prix Liliane Bettencourt, France (1997); Grand Prix Charles-Léopold Mayer of the Académie des Sciences, Paris (2003); Edwin B. Astwood Award, Endocrine Society, USA (2004); Ipsen Award in Endocrinology (2011); Transatlantic Medal of The Society of Endocrinology, UK (2012); Fellow of AAAS (2014). August and Marie Krogh Medal, Denmark (2015); Leonardo da Vinci Gold Medal, FMSI Federation, Italy (2016); Albert Hogan Memorial Award Lecture, University of Missouri (2017); UC Distinguished Faculty Award for Research (2018).

Lysosomes are catabolic organelles devoted to the degradation of intracellular proteins and organelles that are delivered to the lysosomes via autophagy. Lysosome biogenesis and autophagy are very dynamic processes, which are modulated in response to cues. My laboratory has recently identified the fibroblast growth factor (FGF) signalling as main regulator of post-natal activation of autophagy and lysosome biogenesis in chondrocytes of the cartilage during bone growth. This process is mediated by the FGFR3 and FGFR4 receptors through both transcriptional and post-translational mechanisms. The FGF-mediated induction of lysosomal catabolism is required to remodel the endoplasmic reticulum (ER) of chondrocytes through a process known as ER-phagy. Preliminary data indicate that ER-phagy promotes chondrocyte hypertrophic differentiation and collagen production. Our findings unveil an unexpected role of the lysosome/autophagy pathway in organismal development and growth.
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My research has focused on the lysosome, autophagy and lysosomal storage disorders for the last 15 years. During my PhD (2004-2007) at the Telethon Institute of Genetics and Medicine I studied the role of autophagy in the pathogenesis of Lysosomal Storage Disorders (LSDs) and demonstrated that an impairment of autophagy accounts for part of the phenotypic manifestation LSDs, defining these disorders as "autophagic disorders' (Settembre et al. 2008). Subsequently (in 2007) I moved to United States as visiting student and subsequently as post-doctoral fellow in the laboratory of Dr. Karsenty (Columbia University, NY) where I was involved in the study of the role of proteoglycans during skeletal development and growth (Settembre et al. 2008). In 2009, I moved to Houston at Baylor College of Medicine where I focused on the basic biological mechanisms regulating lysosome and autophagosome biogenesis and found that the formation of these organelles is co-regulated at the transcriptional level through the activity of a master transcription factor, TFEB (Settembre et al 2011). These studies also led me to identify a lysosome to nucleus signaling mechanism, through which the lysosome can control its biogenesis and function in response to environmental cues (Settembre et al. 2012). In 2013 I returned to Italy as assistant investigator at the Telethon Institute of Genetic and Medicine (TIGEM) and assistant professor at the Federico II University of Naples. IN 2016 I was selected as EMBO Young Investigator and my laboratory received the ERC starting grant. The main research interest of my lab is to study the role of lysosomal and autophagy pathways during bone growth and maintenance and develop novel therapeutic approaches for the treatment of skeletal abnormalities in genetic disorders (Cinque et al.2015, Bartolomeo et al. 2017, Forrester et al. submitted).

Engineering of three-dimensional human skeletal muscle tissues is motivated by the need for improved physiological systems that would serve for modelling and studying of muscle diseases, pre-clinical drug development, and potential muscle regenerative therapies. In this talk, I will describe first-time engineering of contractile human engineered muscle tissues made of primary myogenic cells derived from muscle biopsies and myogenic progenitors derived from induced pluripotent stem cells by transient overexpression of satellite cell marker Pax7. Resulting bioengineered muscle microtissues ("myobundles") exhibit aligned architecture, multinucleated and striated myofibers, and a Pax7^+^ cell pool. They contract spontaneously and respond to electrical stimuli with robust calcium transients, twitch and tetanic contractions. During culture, myobundles maintain functional acetylcholine receptors and structurally and functionally mature, as evidenced by increased myofiber diameter, improved calcium handling and contractile strength, formation of triads, localization of dystrophin in sarcolemma, and enhanced expression of various maturation genes. In response to diversely acting drugs, myobundles undergo dose-dependent hypertrophy or toxic myopathy similar to clinical outcomes. In response to exercise-mimetic electrical stimulation, myobundles undergo significant hyperplastic and hypertrophic growth, enhanced force-generating capacity, and increased metabolic flux. When derived using cells from patients with congenital skeletal muscle diseases, myobundles exhibit expected pathological phenotypes. Upon implantation into immunocompromised mice for 3 weeks, the myobundles progressively vascularize and maintain functionality. Overall, biomimetic human myobundles provide an enabling platform for predictive drug and toxicology screening and development of novel therapeutics for degenerative muscle disorders.
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Dr. Nenad Bursac is a Professor of Biomedical Engineering, Cell Biology, and Medicine at Duke University and one of the pioneers and leaders of the cardiac and skeletal muscle tissue engineering fields. In 1999, as a member of Dr. Robert Langer' group at MIT, he demonstrated the first engineering of functional heart tissues using mammalian cardiomyocytes. His postdoctoral research with Dr. Leslie Tung at Johns Hopkins University resulted in new methods to control architecture and function of 2- and 3-dimensional heart cell cultures. Currently, Dr. Bursac\'s research involves use of cell, tissue, and genetic engineering techniques and electrophysiological and biomechanical studies to advance fields of somatic and stem cell based therapies for heart and skeletal muscle disease.

For the last 20 years, Dr. Bursac's work has pushed the boundaries of the field by demonstrating a number of "firsts", including: the first use of bioreactors for functional cardiac tissue engineering; the first studies of electrophysiology and arrhythmias in engineered heart tissues; the first engineering of anisotropic cardiac tissue patch and methods to control patch anisotropy; the most functionally advanced mouse cardiac tissue patch; the first engineering of highly functional, large (40mmx40mm) heart tissues from human pluripotent stem cells; first engineering of functional human skeletal muscle tissues from primary and pluripotent stem cells; and first engineering of biosynthetic excitable cells and tissues for studies and treatment of cardiac arrhythmias and heart failure.

Dr. Bursac has authored more than 100 scientific manuscripts, presented over 120 invited talks, and has mentored more than 30 PhD students and postdoctoral and medical fellows. He co-directs Regeneration Next Initiative at Duke University. He is a recipient of the Stansell Family Distinguished Research Award, Mendel Center Award, and Stem Cell Innovation Award. In 2014, Dr. Bursac was the president of the North Carolina Tissue Engineering and Regenerative Medicine Society. Since 2015, Dr. Bursac has been a Fellow of American Institute for Medical and Biological Engineering and since 2018 a Fellow of Biomedical Engineering Society. Dr. Bursac has served on various NIH grant review panels and is a member of editorial boards of *Nature Scientific Reports* and *NPJ Regenerative Medicine.*
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